Review article · 2022

Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions

Jindi Huang, Liye Chen, Jiangxia Wu, Daiqiao Ai, Jiquan Zhang, Tie‐Gen Chen, Ling Wang

Journal of Medicinal Chemistry, 65(24), 16033–16061 · Published 12 December 2022 · DOI 10.1021/acs.jmedchem.2c01070

View at the publisherCite this paper

In brief

“Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions” is a 2022 review article by Jindi Huang and 6 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 169 citations as of 21 November 2026, which puts it in the top 1% of works published in 2022 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
169
Most cited in
2025 (55)
Field-weighted impact
2.81
References
205
Authors
7

Abstract

The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is one of the most important intracellular pathways involved in cell proliferation, growth, differentiation, and survival. Therefore, this route is a prospective biological target for treating various human diseases, such as tumors, neurodegenerative diseases, pulmonary fibrosis, and diabetes. An increasing number of clinical… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Huang, J., Chen, L., Wu, J., Ai, D., Zhang, J., Chen, T., & Wang, L. (2022). Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. Journal of Medicinal Chemistry, 65(24), 16033–16061. https://doi.org/10.1021/acs.jmedchem.2c01070

MLA 9

Huang, Jindi, et al. “Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.” Journal of Medicinal Chemistry, vol. 65, no. 24, 2022, pp. 16033–16061. https://doi.org/10.1021/acs.jmedchem.2c01070.

Chicago

Huang, Jindi, Liye Chen, Jiangxia Wu, Daiqiao Ai, Jiquan Zhang, Tie‐Gen Chen, and Ling Wang. 2022. “Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.” Journal of Medicinal Chemistry 65 (24): 16033–16061. https://doi.org/10.1021/acs.jmedchem.2c01070.

Harvard

Huang, J. et al. (2022) ‘Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions’, Journal of Medicinal Chemistry, 65(24), pp. 16033–16061. doi:10.1021/acs.jmedchem.2c01070.

IEEE

J. Huang et al., “Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions,” Journal of Medicinal Chemistry, vol. 65, no. 24, pp. 16033–16061, 2022, doi: 10.1021/acs.jmedchem.2c01070.

BibTeX

@article{huang2022targeting,
  title     = {{Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions}},
  author    = {Huang, Jindi and Chen, Liye and Wu, Jiangxia and Ai, Daiqiao and Zhang, Jiquan and Chen, Tie‐Gen and Wang, Ling},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2022},
  volume    = {65},
  number    = {24},
  pages     = {16033--16061},
  doi       = {10.1021/acs.jmedchem.2c01070},
  url       = {https://doi.org/10.1021/acs.jmedchem.2c01070}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20232323
20244141
20255555
20265050

Its field-weighted citation impact is 2.81: it has been cited 2.81 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer

  • PI3K/AKT/mTOR pathway
  • PI3K inhibitors
  • AKT inhibitors
  • mTOR inhibitors
  • allosteric inhibitors
  • covalent inhibitors
  • PROTACs
  • ATP-competitive inhibitors

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Huang, J., Chen, L., Wu, J., Ai, D., Zhang, J., Chen, T., & Wang, L. (2022). Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. Journal of Medicinal Chemistry, 65(24), 16033–16061. https://doi.org/10.1021/acs.jmedchem.2c01070

How many times has this paper been cited?

169 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Jindi Huang, Liye Chen, Jiangxia Wu, Daiqiao Ai, Jiquan Zhang, Tie‐Gen Chen, Ling Wang.

What is the DOI of this paper?

10.1021/acs.jmedchem.2c01070, permanently at https://doi.org/10.1021/acs.jmedchem.2c01070. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.